RenovoRx Reports Second Quarter 2022 Financial Results
RenovoRx today reported its financial results for the quarter ended June 30, 2022.
RenovoRx Reports Second Quarter 2022 Financial Results
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022.